Company: NCEL
Filing Date: 2025-06-16
Form Type: 425
Source: 0001213900-25-054487
Chunk: 6

Company: NewcelX Ltd.
Filing Date: 2025-06-16
Form: 425
Chunk 6
---
LS and Kadimastem. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS
AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY
AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED
TRANSACTION. Investors and security holders will be able to obtain free copies of the proxy statement/prospectus (if and when available)
and other documents containing important information about NLS and Kadimastem and the proposed transaction, once such documents are filed
with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company
will be available free of charge on NLS’s website at www.nlspharma.com.

Participants in the Solicitation

NLS, Kadimastem, and certain of their respective
directors and executive officers may be deemed to be participants in the solicitation of proxies from NLS and Kadimastem shareholders
in respect of the proposed transaction. Information about the directors and executive officers of NLS, including a description of their
direct or indirect interests, by security holdings or otherwise, is set forth in NLS’s Annual Report on Form 20-F for the fiscal
year ended December 31, 2024, which was filed with the SEC on May 16, 2025. Other information regarding the participants in the proxy
solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy
statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger when such materials become available.
Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions.
You may obtain free copies of these documents from NLS Pharmaceutics using the sources indicated above.

NLS Contacts:

InvestorRelations@nls-pharma.com
www.nlspharma.com

Kadimastem Contacts:

Sarah Bazak, Investors
relations

s.bazak@kadimastem.com

www.kadimastem.com

<div align='center'>4</div>